Metal Ions and Metal Complexes in Alzheimer’s Disease

Author(s): Angelo Spinello, Riccardo Bonsignore, Giampaolo Barone, Bernhard K. Keppler, Alessio Terenzi

Journal Name: Current Pharmaceutical Design

Volume 22 , Issue 26 , 2016

Become EABM
Become Reviewer


Background: Alzheimer’s disease (AD) is the most common form of dementia that seriously affects daily life. Even if AD pathogenesis is still subject of debate, it is generally accepted that cerebral cortex plaques formed by aggregated amyloid-β (Aβ) peptides can be considered a characteristic pathological hallmark. It is well known that metal ions play an important role in the aggregation process of Aβ. Methods: This review focuses on the anti-Aβ aggregation activity of chelating ligands as well as on the use of metal complexes as diagnostic probes and as potential drugs. Conclusion: While chelating agents, such as curcumin or flavonoid derivatives, are currently used to capture metal ions responsible for Aβ aggregation, the potential application of platinum, ruthenium and cobalt complexes, among others, of several heterocyclic ligands, represents a promising new strategy to fight AD.

Keywords: Alzheimer’s Disease, metal ions, metal complexes, AD drugs, anti-Aβ aggregating agents, imaging.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2016
Page: [3996 - 4010]
Pages: 15
DOI: 10.2174/1381612822666160520115248
Price: $65

Article Metrics

PDF: 51